Avestar Capital LLC Buys 45 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Avestar Capital LLC grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 804 shares of the company’s stock after purchasing an additional 45 shares during the period. Avestar Capital LLC’s holdings in IDEXX Laboratories were worth $332,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $31,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $37,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Down 3.3 %

NASDAQ:IDXX opened at $444.53 on Friday. The company has a market cap of $36.40 billion, a P/E ratio of 41.66, a P/E/G ratio of 3.47 and a beta of 1.37. The stock’s fifty day moving average price is $430.77 and its two-hundred day moving average price is $453.31. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 13,330 shares of company stock worth $6,161,276 over the last 90 days. Corporate insiders own 2.11% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of recent research reports. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Bank of America upped their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Finally, Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.